Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Silence Therapeutics strengthens the business with two key appointments

The drug developer has drafted in a new director as well as recruiting a head of clinical development
boardroom table
There will be a new face around the boardroom table

Silence Therapeutics PLC (LON:SLN) has made two key appointments that will respectively strengthen the board and the business. 

Dave Lemus, currently chief operating officer and chief financial officer of Proteros  Biostructures, has been appointed an independent director.  

READ: Silence Therapeutics on track to be a clinical stage company by year-end

Chairman Annalisa Jenkins said: "Dave has joined at a pivotal time for the company. His successful track record and proven leadership in building and managing high performance management teams will strengthen our capabilities as we continue to maximise the potential of our GalNAc-based SRNi platform."

Meanwhile, Richard Jenkins comes on board as head of clinical development, replacing chief scientific officer Torsten Hoffmann who is leaving Silence for personal reasons.

Jenkins, who has worked for Takeda and GlaxoSmithKline, will oversee the development of the company's main drug candidate, a compound for iron overload, as it progresses towards clinical trials. He will report directly to chairman Jenkins.

 

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use